Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved for the treatment of
patients affected by major depressive disorder (MDD), generalized anxiety disorder (GAD) …

Background: Duloxetine hydrochloride (DUL) is an antidepressant included in the
pharmacological class of serotonin–norepinephrine reuptake inhibitors approved for the …

Objective: The safety and tolerability of duloxetine for major depressive disorder (MDD),
generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP) …

Duloxetine - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC
Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog Tech blog …

Background: Second-generation antidepressants dominate the management of patients with
major depressive disorder (MDD). Evidence on the general and comparative benefits and …

OBJECTIVE: This analysis focuses on efficacy and safety data obtained from studies of
duloxetine for the treatment of major depressive disorder (MDD) within the approved dose …

Background: Depression is a chronic recurring disorder and guidelines recommend long-
term therapy. This clinical trial evaluated the long-term (1 year) safety and efficacy of …

Background: Duloxetine is a balanced and potent dual reuptake inhibitor of serotonin (5-HT)
and norepinephrine (NE) that has previously been shown to be effective in the acute …

Background Major depressive disorder (MDD) is a chronic and highly disabling condition.
Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients …

Duloxetine is the first relatively balanced serotonin and noradrenaline re-uptake inhibitor to
be widely available for three indications including: major depressive disorder, peripheral …